Last updated on July 2018

Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Brief description of study

This two-part, open-label extension and safety monitoring study will examine the safety and efficacy of continued etrolizumab treatment in patients with moderate to severely active Crohn's disease who were previously enrolled in the etrolizumab Phase III Study GA29144.

Clinical Study Identifier: NCT02403323

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: GA29145 ...

Azienda Ospedaliero Universitaria di Parma; Clinica Pediatrica
Parma, Italy
  Connect »